** U.S.-listed shares of cancer drug developer BeiGene 688235.SS, ONC.O fall 3.2% to $266.03
** Co says it is discontinuing development of its experimental lung cancer drug, ociperlimab, in a late-stage trial
** Independent data monitoring committee recommended terminating the trial
** Study unlikely to meet the main goal of improving overall survival, co says
** As of last close, ONC up ~49% YTD vs. 2.4% decline in the Nasdaq biotechnology index .NBI
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.